VEGFA and peripheral arterial disease: In conclusion, despite the nonrandomized, no-blinded design and relative small size, results concluded from the study provide initial evidences of the efficacy and safety of autologous CD133+ cells treatment for diabetic PAD, as well as the immunoregulatory impact of VEGF and IL-6 paracrine.